Navigation Links
Ausio Pharmaceuticals to Present at Bio(R) 2009
Date:5/14/2009

Initial results from preclinical and Phase 1 safety studies, and plans for Phase 2 studies for menopausal symptoms and benign prostatic hyperplasia (BPH) are to be presented

CINCINNATI, May 14 /PRNewswire/ -- Ausio Pharmaceuticals, LLC, a biotechnology development company focused on medicines for an aging global population, will lead off the Bio(R) Business Forum in a presentation on May 19, 2009 at 9:00 AM in Atlanta, Georgia. Ausio has developed AUS-131, a pharmaceutical formulation of the soy metabolite S-equol. AUS-131 is expected to provide soy health benefits by consistently delivering therapeutically appropriate levels of S-equol, validated in clinical trial programs. Ausio has successfully completed two Phase 1 clinical trials for AUS-131, and Phase 2 studies are scheduled for treatment of menopausal symptoms and BPH.

AUS-131 Preclinical and Phase 1 Clinical Results

AUS-131 is pure, synthetic S-equol, a soy metabolite, and acts as a nonsteroidal, nonhormonal, selective estrogen receptor beta (ER beta) agonist. The safety profile of AUS-131 in FDA-required preclinical studies was excellent, and AUS-131 has demonstrated positive effects in rodent models of menopausal hot flashes and BPH, supporting its promise for the treatment of these conditions in humans. In Phase 1 trials, AUS-131 demonstrated a favorable safety and pharmacokinetic profile, with no significant drug-related adverse events at doses several-fold higher than the expected therapeutic range.

Phase 2 clinical trials to assess the efficacy of AUS-131 for relief of menopausal symptoms and BPH are on schedule to begin September 2009. The expected completion date for the Phase 2 clinical trials is Q2 2010.

About AUS-131

AUS-131 is pure, synthetic S-equol, a potent metabolite of the soy isoflavone, daidzein, which is produced in only a subset of individuals. AUS-131 is a first-in-class, nonsteroidal, nonhormonal, selective ER beta agonist that has the potential to provide therapeutic benefits with an excellent safety profile compared to estrogen. AUS-131 is being evaluated for a wide range of indications, including menopausal symptoms, benign prostatic hyperplasia, osteoporosis, and topical applications.

About Ausio (www.ausiopharma.com)

Ausio Pharmaceuticals, LLC is a global biotechnology development company committed to cultivating key partnerships with the goal of advancing medicines for an aging population. Ausio was founded in 2006 based on technologies licensed from the Australian Health and Nutrition Association Ltd, NSW, Australia and Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio and has garnered strong patent position for its lead compound, AUS-131.


'/>"/>
SOURCE Ausio Pharmaceuticals, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... ... digital pathology, today announced their digital pathology technology has the potential to eliminate ... five medical centers in The Netherlands as part of the 2017 ISBI ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... flow controllers based on capillary thermal mass flow technology provide exponentially more accurate ... applications. Over 80% of all industrial processes—such as those involving chemical reactions, ...
(Date:4/27/2017)... a distinguished resource for research, development and commercialization of ... Thomas C. Seoh as President and CEO. Mr. Seoh ... becomes Executive Chairman and will continue to serve as ... Thomas Seoh commented, "I am excited and honored ... firm,s remarkable team of life science professionals, all of ...
(Date:4/26/2017)... ... April 26, 2017 , ... Baltimore bio ... MailGuardtm mail security screening solution at the National Postal Forum 2017 in Baltimore, ... a fast, highly accurate, easy to use and low cost threat detection solution ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
Breaking Biology News(10 mins):